Search Results

Synlogic, Inc. announced that it has entered into an approximately $1 million subcontract under an Air Force Research Lab prime contract to develop a manufacturing process to support development of a potential live probiotic product.

Synlogic, Inc. (Nasdaq: SYBX) announced today the publication of a manuscript detailing the development and activity of SYNB1353 in preclinical models and demonstrating safety, tolerability, and clinical proof of mechanism in healthy volunteers through the successful lowering of methionine (Met), a precursor to homocysteine, in a dietary model of classical homocystinuria (HCU).

Synlogic, Inc. announced that an abstract outlining the SYNB1353 program as a potential treatment for homocystinuria (HCU) has been accepted and will be presented at the International Conference on Microbiome Engineering 2023, held in Berkeley, California on December 8th to 10th.

Synlogic, Inc. announced that CEO Aoife Brennan, M.B. Ch.B., has been honored as a PharmaVoice 100 winner, a list recognizing the most inspiring people in the life sciences industry.

Synlogic, Inc. announced the pricing of an underwritten public offering of 7,394,363 shares of common stock and accompanying common warrants to purchase up to an aggregate of 7,394,363 shares of common stock.

Synlogic, Inc. today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO-INN) has selected “labafenogene marselecobac” for the nonproprietary name of the company’s investigational drug for phenylketonuria (PKU), previously known as SYNB1934.

Synlogic, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to labafenogene marselecobac for the treatment of phenylketonuria.

Synlogic, Inc., the leading company advancing therapeutics based on synthetic biology, reminded stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Thursday, June 15, 2023 at 8:00 a.m. EST.

Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that its management team will participate in the SVB Securities Healthcare Therapeutics Forum, being held in New York, July 11-12, 2023.

Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ has been chosen by Synlogic, (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options.